Disease Intelligence Center · Pandemic I & II
PCOS & Hormonal Dysregulation
PCOS is approached as a metabolic–endocrine phenotype: androgen and insulin signaling, adipose inflammation, nutrient status and endocrine-active exposures are evaluated side by side.
Domain weighting
Organizational emphasisiWeightings describe where this framework directs attention for this condition. They are not a measure of how much any factor caused an individual case.
Root-cause chain
Each link carries its own evidence grade- Hyperinsulinemia→Ovarian androgen productionBA
Insulin amplifies LH-driven theca-cell androgen synthesis and lowers SHBG.
Relationship: Established causal
- Adipose inflammation→Insulin resistanceIB
Cytokine signaling contributes to peripheral insulin resistance in PCOS cohorts.
Relationship: Observational association
- Endocrine-active exposure (e.g. bisphenols)→Androgen and SHBG alterationTC
Cross-sectional studies report higher urinary bisphenol levels in PCOS; direction of effect is unresolved.
Relationship: Observational association
- Inositol and vitamin D insufficiency→Ovulatory dysfunctionNC
Small trials report improved ovulatory frequency with myo-inositol; effect sizes vary.
Relationship: Randomized evidence
iDetection of an exposure does not establish that it caused a disease. This platform separates exposure, association, plausible mechanism, clinical evidence and demonstrated causation.
Fifth Estate considerations
Microbial ecologyGut bacteriome and bile-acid patterns are tracked as potential modifiers of androgen metabolism, framed explicitly as a hypothesis.
Go deeper
TOBIN Intelligence LibraryThe full evidence review for PCOS & Hormonal Dysregulation: each mechanism by domain, what is established versus uncertain, related pandemics, relevant labs and how they move your scores.
Open the PCOS & Hormonal Dysregulation evidence reviewProtocol Fusion Engine
Six lanes · evidence grade and regulatory status on every entryConventional
First-line for menstrual regulation and hyperandrogenism.
Caution: Thrombotic risk; contraindicated in migraine with aura, smoking over 35, prior VTE.
Higher live-birth rate than clomiphene in PCOS.
Caution: Requires fertility monitoring; not for use in pregnancy.
Functional
Improves ovulatory function and metabolic markers.
Caution: Avoid restrictive patterns in disordered-eating history.
Orthomolecular
Modest improvements in ovulation and insulin indices in small trials.
Caution: GI upset; monitor glucose with concurrent insulin sensitizers.
Traditional
Small trials report reduced free testosterone.
Caution: Not adequate for significant hyperandrogenism.
Energy / Physical
Energy medicine on Tayapulse →Trials show no reliable improvement in live birth rate.
Caution: Should not displace ovulation induction when pregnancy is the goal.
iLanes are presented side by side so the difference in evidence strength is visible. Nothing here is a prescription, and interactions must be reviewed with your clinician and pharmacist.
iEnergy and physical modalities in this lane are explored further with Tayapulse. Evidence grade and regulatory status still apply: these are adjuncts used only where indicated, never cures or replacements for guideline care.
Diagnostics to consider
- · Total and free testosterone, SHBG, DHEAS
- · LH, FSH, AMH where indicated
- · Fasting insulin, glucose, HbA1c
- · Thyroid and prolactin to exclude mimics
- · Pelvic ultrasound per criteria
Monitoring
- · Cycle regularity log
- · Androgenic symptom score
- · Metabolic panel every 6–12 months
Prevention emphasis
- · Insulin-sensitizing dietary pattern
- · Resistance training
- · Reduce avoidable endocrine-active exposures
- · Early metabolic screening in family history